Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ONCOSEC MEDICAL IncONCS · Entity 117092 | Director | January 02, 2019 | January 04, 2019 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director · Chief Executive Officer | August 07, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ONCOSEC MEDICAL Inc
Report date January 02, 2019 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-01-02 | Direct | 50,000 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 50,000 · Balance 50,000 F1: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021 pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021 pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.
Skye Bioscience, Inc.
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,419,823 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 1,090,000 · Balance 1,419,823 F1: Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 9,343 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,343 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arch Therapeutics, Inc.
Report date November 10, 2022 · Filed November 11, 2022
Section 16 reporting ended · disclosed 2021-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2032-11-10 | Direct | 250,000 |
Reported balance
After 2022-11-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-10 · Grant · Acquired 250,000 · Balance 250,000 F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 12 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 12 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 7, 2026 21:37 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 1,090,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-054941 · wk-form4_1786138670.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,419,823 F1 · shares: Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,586 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 14 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,586 shares Expires 2033-09-29 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 21,586 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 13 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,586 Underlying: Common Stock · 21,586 shares Expires 2033-09-29 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F7 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,013 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 12 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,013 shares Expires 2033-11-06 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 9,013 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 11 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,013 Underlying: Common Stock · 9,013 shares Expires 2033-11-06 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F6 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $14.56 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 10 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 9 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F5 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 650,000 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 8 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650,000 shares Expires 2034-10-27 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 650,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 7 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2034-10-27 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F4 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,360 | Not disclosed Strike: $14.50 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 6 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,360 shares Expires 2031-12-14 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 12,360 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 5 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,360 Underlying: Common Stock · 12,360 shares Expires 2031-12-14 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,000 | Not disclosed Strike: $11.25 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2030-08-07 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 36,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2030-08-07 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $2.89 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:06 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-26-023337 · wk-form4_1775167579.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F1 · derivative.exercise_price: The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. F3 · price: On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006618 · wk-form4_1770688448.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:43 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000010 · wk-form4_1740609817.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 02:20 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 82,546 | $4.99 | $411,904.54 |
DisclosureSEC source: 0001516551-24-000116 · wk-form4_1732069239.xml · nonDerivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,823 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| November 15, 2024 Filed Nov 20, 2024 02:20 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 364 | $5.55 | $2,020.20 |
DisclosureSEC source: 0001516551-24-000116 · wk-form4_1732069239.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,369 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person. Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 00:31 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001516551-24-000101 · wk-form4_1730334676.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 21:20 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | OtherCommon Stock | 15,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-24-000078 · wk-form4_1724793636.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,733 F1 · kind: Shares received by reporting person in connection with one of Issuer's shareholders pro rata distribution of common stock of Issuer to its shareholders. F1 · price: Shares received by reporting person in connection with one of Issuer's shareholders pro rata distribution of common stock of Issuer to its shareholders. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 23:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000010 · wk-form4_1709335471.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 23:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-24-000010 · wk-form4_1709335471.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,006 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 11:13 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000014 · wk-form4a_1709550818.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-03-01 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 11:13 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-24-000014 · wk-form4a_1709550818.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,006 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 01:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 21,586 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001516551-23-000095 · wk-form4_1699320579.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,599 Underlying: Common Stock · 21,586 shares Expires 2033-08-25 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 01:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 194,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-23-000095 · wk-form4_1699320579.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,006 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 29, 2023 Filed Aug 29, 2023 22:39 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | PurchaseCommon Stock | 881,000 | $0.02 | $16,474.70 |
DisclosureSEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,554,828 Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 15:26 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | PurchaseCommon Stock | 881,000 | $0.02 | $16,474.70 |
DisclosureSEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,683,957 Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 22:39 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | OtherCommon Stock | 110,000 | $0.02 | $1,881.00 |
DisclosureSEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,673,828 Read SEC document |
| August 28, 2023 Filed Aug 31, 2023 15:26 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | OtherCommon Stock | 110,000 | $0.02 | $1,881.00 |
DisclosureSEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,802,957 Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 22:39 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 2,253,046 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · derivative · entry 5 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,253,046 Underlying: Common Stock · 2,253,046 shares Expires 2033-08-25 F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 22:39 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 20,277,414 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,554,828 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 25, 2023 Filed Aug 31, 2023 15:26 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 2,253,046 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · derivative · entry 6 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,253,046 Underlying: Common Stock · 2,253,046 shares Expires 2033-08-25 F4 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| August 25, 2023 Filed Aug 31, 2023 15:26 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 20,277,414 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,683,957 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 23, 2023 Filed Aug 29, 2023 22:39 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | OtherCommon Stock | 9,000 | $0.01 | $106.20 |
DisclosureSEC source: 0001516551-23-000062 · wk-form4_1693348773.xml · nonDerivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,563,828 Read SEC document |
| August 23, 2023 Filed Aug 31, 2023 15:26 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | OtherCommon Stock | 9,000 | $0.01 | $106.20 |
DisclosureSEC source: 0001516551-23-000069 · wk-form4a_1693495603.xml · nonDerivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,692,957 Read SEC document |
| November 10, 2022 Filed Nov 11, 2022 02:54 UTC | Arch Therapeutics, Inc. ARTH · Entity 109849 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001415889-22-011314 · form4-11112022_021112.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-11-10 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 12 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 292,500 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 6 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,500 Underlying: Common Stock · 292,500 shares Expires 2025-08-03 F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F6 · derivative.exercise_date: 8.33% of the options vested on the grant date of August 3, 2020. An additional 8.333% of the options vest on each monthly anniversary of the grant date. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 487,500 | Not disclosed Strike: $0.06 | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 5 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,500 Underlying: Common Stock · 487,500 shares Expires 2025-04-27 F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · derivative.exercise_date: The options underlying this award are fully vested. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 390,000 | Not disclosed Strike: $0.11 | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 4 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2025-02-06 F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F5 · derivative.exercise_date: Options will vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 390,000 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 3 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2024-04-03 F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · derivative.exercise_date: The options underlying this award are fully vested. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 2,335,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · nonDerivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 2,335,721 F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F2 · ownership.nature: The shares are held by a trust for which the Reporting Person is a trustee and has voting and dispositive power over the shares. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 18:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 1,406,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,406,543 F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 00:03 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 3,090,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001516551-21-000029 · wf-form4_163969937662511.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,090,000 Underlying: Common Stock · 3,090,000 shares Expires 2031-12-14 F3 · derivative.exercise_date: The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 00:03 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001516551-21-000029 · wf-form4_163969937662511.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 27, 2021 Filed Oct 1, 2021 12:11 UTC | Arch Therapeutics, Inc. ARTH · Entity 109849 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001104659-21-121632 · tm2129012d2_4.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-09-26 F2 · derivative.exercise_date: The option was granted pursuant to the Plan. 1/3 of the option vested on the grant date and the remainder of the option shall vest equally on each of the first 24 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. Read SEC document |
| September 27, 2021 Filed Oct 1, 2021 12:11 UTC | Arch Therapeutics, Inc. ARTH · Entity 109849 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001104659-21-121632 · tm2129012d2_4.xml · derivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-09-26 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 18:53 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | GrantEmployee Option Grant (Right to Buy) · Derivative | 9,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001640334-20-002027 · form4.xml · derivative · entry 2 DHILLON PUNIT · CIK 0001425052 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200,000 Underlying: Common Stock · 9,000,000 shares Expires 2030-08-07 F2 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four and a half years. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 18:53 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | PurchaseCommon Stock | 1,000,000 | $100,000.00 | $100,000,000,000.00 |
DisclosureSEC source: 0001640334-20-002027 · form4.xml · nonDerivative · entry 1 DHILLON PUNIT · CIK 0001425052 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 F1 · price: Private purchase transaction from Emerald Health Sciences at $0.10 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.